Latest Conference Articles

February 12th 2021, 7:45pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - Atezolizumab monotherapy showed favorable outcomes compared with chemotherapy alone as frontline treatment for patients with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma.

February 12th 2021, 7:38pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - The novel prostate specific membrane antigen–targeted radiopharmaceutical for PET imaging technique, 18F-DCFPyL, demonstrated potential in identifying occult prostate cancer and more accurately characterizing disease burden.

February 12th 2021, 6:25pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.

February 12th 2021, 5:24pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - Patients with advanced renal cell carcinoma reported improved health-related quality of life when treated with nivolumab plus cabozantinib compared with sunitinib

February 12th 2021, 4:38pm

Transplantation and Cellular Therapy Meetings

February 12, 2021 - Ruxolitinib demonstrated a significantly higher overall response rate compared with best available therapy among adolescent and adult patients with chronic graft-versus-host disease.

February 11th 2021, 11:08pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - Eganelisib, a novel PI3K-y inhibitor, demonstrated higher responses rates with nivolumab in patients with metastatic urothelial carcinoma.

February 11th 2021, 11:05pm

Genitourinary Cancers Symposium (ASCO GU)

Tian Zhang, MD, discusses the goal of the ongoing PDIGREE trial examining nivolumab and ipilimumab plus cabozantinib in patients with metastatic untreated renal cell cancer.

February 11th 2021, 11:03pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

February 11th 2021, 10:59pm

Transplantation and Cellular Therapy Meetings

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.

February 11th 2021, 10:54pm

Transplantation and Cellular Therapy Meetings

Rajneesh Nath, MD, discusses the interim results of the phase 3 SIERRA trial in patients with relapsed/refractory acute myeloid leukemia.

February 11th 2021, 10:27pm

Transplantation and Cellular Therapy Meetings

February 11, 2021 - Treatment with the first-generation precision cell therapy Orca-T led to a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, a lack of treatment-related mortalities, while showcasing scalability potential.

February 11th 2021, 10:10pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - Avelumab as frontline maintenance therapy plus best supportive care showed a favorable benefit-risk balance in Japanese patients with advanced urothelial cancer that did not progress on first-line chemotherapy.

February 11th 2021, 9:00pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - The novel tubulin inhibitor VERU-111 demonstrated early antitumor activity and a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer who failed a prior androgen receptor–targeting agent.

February 11th 2021, 8:40pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - First-line treatment with immune checkpoint inhibitor–based regimens could be linked with an improvement in overall survival versus select targeted therapies in patients with metastatic non–clear cell renal cell carcinoma.

February 11th 2021, 8:03pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - Sapanisertib failed to show significant activity and a favorable toxicity profile in patients with refractory metastatic renal cell carcinoma regardless of mTOR or PTEN status.

February 11th 2021, 6:44pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - A higher starting dose of lenvatinib — 18 mg per day — improved health-related quality of life and led to longer time to deterioration compared with a lower starting dose of lenvatinib — 14 mg per day — in patients with renal cell carcinoma.

February 11th 2021, 6:13pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - Lenvatinib in combination with everolimus has proven to be safe and effective when used in the treatment of patients with clear cell renal cell carcinoma who had previously received an immune checkpoint inhibitor.

February 11th 2021, 4:15pm

Transplantation and Cellular Therapy Meetings

February 11, 2021 - A conditioning regimen comprised of targeted radiation with Iomab-B led to a lower incidence of sepsis as well as trends toward reduced rates of severe mucositis and febrile neutropenia versus conventional care and standard conditioning regimens in older adults with relapsed or refractory acute myeloid leukemia.

February 11th 2021, 3:17pm

Transplantation and Cellular Therapy Meetings

February 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia.

February 11th 2021, 3:06pm

Genitourinary Cancers Symposium (ASCO GU)

Atish D. Choudhury, MD, PhD, discusses the rationale behind combining pembrolizumab with radium-223 in patients with metastatic castration-resistant prostate cancer as part of a phase 2 clinical trial.